ABEONA THERAPEUT. DL-01 - Asset Resilience Ratio

Latest as of December 2025: 51.45%

ABEONA THERAPEUT. DL-01 (PCJ) has an Asset Resilience Ratio of 51.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PCJ total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

€112.97 Million
≈ $132.07 Million USD Cash + Short-term Investments

Total Assets

€219.57 Million
≈ $256.70 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how ABEONA THERAPEUT. DL-01's Asset Resilience Ratio has changed over time. See net assets of ABEONA THERAPEUT. DL-01 for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down ABEONA THERAPEUT. DL-01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PCJ market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €112.97 Million 51.45%
Total Liquid Assets €112.97 Million 51.45%

Asset Resilience Insights

  • Very High Liquidity: ABEONA THERAPEUT. DL-01 maintains exceptional liquid asset reserves at 51.45% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

ABEONA THERAPEUT. DL-01 Industry Peers by Asset Resilience Ratio

Compare ABEONA THERAPEUT. DL-01's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Biotechnology 33.70%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
Biotechnology 11.64%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
Biotechnology 2.21%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 82.25%

Annual Asset Resilience Ratio for ABEONA THERAPEUT. DL-01 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for ABEONA THERAPEUT. DL-01.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 51.45% €112.97 Million
≈ $132.07 Million
€219.57 Million
≈ $256.70 Million
-16.82pp
2024-12-31 68.27% €74.36 Million
≈ $86.94 Million
€108.93 Million
≈ $127.35 Million
+9.28pp
2023-12-31 58.99% €37.75 Million
≈ $44.14 Million
€64.00 Million
≈ $74.83 Million
-0.08pp
2022-12-31 59.07% €37.93 Million
≈ $44.35 Million
€64.21 Million
≈ $75.07 Million
+43.89pp
2021-12-31 15.19% €12.09 Million
≈ $14.13 Million
€79.59 Million
≈ $93.04 Million
--
pp = percentage points

About ABEONA THERAPEUT. DL-01

F:PCJ Germany Biotechnology
Market Cap
$305.58 Million
€261.38 Million EUR
Market Cap Rank
#15318 Global
#1496 in Germany
Share Price
€4.60
Change (1 day)
-1.01%
52-Week Range
€3.56 - €6.10
All Time High
€17.73
About

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more